TrialDrug design, development and therapy2020

First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy Volunteers.

Sungpil Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.